Physician profile
Edward Goldenberg
NPI 1396818191
$3,211.14
in general payments reported to CMS, 2019-2025
21 companies · $14.32 in 2025
The $14.32 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $262 · 2021: $525 · 2022: $667 · 2023: $740 · 2024: $548 · 2025: $14.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $507.08 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $386.18 | 2019-2024 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $353.08 | 2019-2024 | Spravato |
| Sunovion Pharmaceuticals INC. | $348.96 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $279.40 | 2019-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $233.43 | 2020-2024 | Caplyta |
| Corium, LLC | $196.28 | 2022-2023 | Azstarys |
| Allergan, INC. | $177.50 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $161.85 | 2021-2024 | Ingrezza |
| Almatica Pharma LLC | $108.18 | 2022-2025 | Loreev Xr, Gralise |
| Teva Pharmaceuticals USA, INC. | $81.74 | 2022-2024 | Austedo Xr, Austedo |
| Idorsia Pharmaceuticals US INC | $72.25 | 2022-2024 | Quviviq |
| Lundbeck LLC | $71.42 | 2019-2023 | Rexulti |
| Avanir Pharmaceuticals, INC. | $48.51 | 2019 | |
| Shire North American Group INC | $44.39 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $37.86 | 2019 | |
| Tris Pharma INC | $22.62 | 2023 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $22.01 | 2022 | |
| Neuronetics, INC. | $21.46 | 2020 | |
| Bausch Health US, LLC | $20.97 | 2019 | |
| Alkermes, INC. | $15.97 | 2024 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Goldenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.